- NUDT15 gene variants and thiopurine-induced leukopenia in patients with inflammatory bowel disease
-
Matsuoka K
- KMID: 2504582
- Intest Res.
- 2020 Jul;18(3):275-281.
- doi: 10.5217/ir.2020.00002
Thiopurine has been used to maintain remission and to reduce antidrug antibody formation in monoclonal antibody therapy in patients with inflammatory bowel disease (IBD). The use of thiopurine is limited... -
- CITED
-
- Close
- SHARE
-
- Close
- Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods
-
Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu
- KMID: 2070102
- Korean J Intern Med.
- 2014 Jul;29(4):409-415.
The incidence and prevalence of inflammatory bowel diseases (IBDs) including ulcerative colitis and Crohn disease are rapidly increasing in Western countries and in developed Asian countries. Although biologic agents targeting... -
- CITED
-
- Close
- SHARE
-
- Close
- Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis
-
Matsuoka K, Togo K, Yoshii N, Hoshi M, Arai S
- KMID: 2539008
- Intest Res.
- 2023 Jan;21(1):88-99.
- doi: 10.5217/ir.2021.00154
Background/Aims: Patients with ulcerative colitis (UC) are at an increased risk of certain infections and malignancies compared with the general population. Incidence rates (IRs) of hospitalized infections, herpes zoster (HZ),... -
- CITED
-
- Close
- SHARE
-
- Close
- Tacrolimus for the Treatment of Ulcerative Colitis
-
Matsuoka K, Saito E, Fujii T, Takenaka K, Kimura M, Nagahori M, Ohtsuka K, Watanabe M
- KMID: 2174466
- Intest Res.
- 2015 Jul;13(3):219-226.
- doi: 10.5217/ir.2015.13.3.219
Tacrolimus is a calcineurin inhibitor used for the treatment of corticosteroid-refractory ulcerative colitis (UC). Two randomized controlled trials and a number of retrospective studies have assessed the therapeutic effect of... -
- CITED
-
- Close
- SHARE
-
- Close
- Magnetic resonance enterography for the evaluation of the deep small intestine in Crohn's disease
-
Ohtsuka K, Takenaka K, Kitazume Y, Fujii T, Matsuoka K, Kimura M, Nagaishi T, Watanabe M
- KMID: 2425284
- Intest Res.
- 2016 Apr;14(2):120-126.
- doi: 10.5217/ir.2016.14.2.120
For the control of Crohn's disease (CD) a thorough assessment of the small intestine is essential; several modalities may be utilized, with cross-sectional imaging being important. Magnetic resonance (MR) enterography,... -
- CITED
-
- Close
- SHARE
-
- Close
- Fecal microbiota transplantation for recurrent Clostridium difficile infection in a patient with ulcerative colitis
-
Nanki K, Mizuno S, Matsuoka K, Ono K, Sugimoto S, Kiyohara H, Arai M, Nakashima , Takeshita , Saigusa K, Senoh M, Fukuda T, Naganuma M, Kato H, Suda W, Hattori M, Kanai T
- KMID: 2402658
- Intest Res.
- 2018 Jan;16(1):142-146.
- doi: 10.5217/ir.2018.16.1.142
Fecal microbiota transplantation (FMT) has been reported as a safe and effective therapy in patients with refractory and recurrent Clostridium difficile infection (CDI). FMT has also been reported as a... -
- CITED
-
- Close
- SHARE
-
- Close
- Production of cloned sei whale (Balaenoptera borealis) embryos by interspecies somatic cell nuclear transfer using enucleated pig oocytes
-
Lee E, Bhuiyan MM, Watanabe H, Matsuoka K, Fujise Y, Ishikawa H, Fukui Y
- KMID: 1726899
- J Vet Sci.
- 2009 Dec;10(4):285-292.
- doi: 10.4142/jvs.2009.10.4.285
In this study, we examined the feasibility of using subzonal cell injection with electrofusion for interspecies somatic cell nuclear transfer (iSCNT) to produce sei whale embryos and to improve their... -
- CITED
-
- Close
- SHARE
-
- Close
- Association between oral corticosteroid starting dose and the incidence of pneumonia in Japanese patients with ulcerative colitis: a nation-wide claims database study
-
Matsuoka K, Inoue T, Tsuchiya H, Nagano K, Iwahori T
- KMID: 2558192
- Intest Res.
- 2024 Jul;22(3):319-335.
- doi: 10.5217/ir.2023.00071
Background/Aims: A previous study demonstrated that half of patients started oral corticosteroids (OCS) for ulcerative colitis (UC) exacerbations at lower doses than recommended by Japanese treatment guidelines (initial OCS prednisolone... -
- CITED
-
- Close
- SHARE
-
- Close
- 5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
-
Miyoshi J, Matsuoka K, Yoshida A, Naganuma M, Hisamatsu , Yajima T, Inoue N, Okamoto S, Iwao Y, Ogata H, Ueno F, Hibi T, Kanai T
- KMID: 2434166
- Intest Res.
- 2018 Oct;16(4):635-640.
- doi: 10.5217/ir.2018.00015
Ulcerative colitis (UC) is one of the major clinical phenotypes of inflammatory bowel diseases. Although 5-aminosalicylic acid (5-ASA) is widely used for UC and its efficacy and safety have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Vaccination in patients with inflammatory bowel disease–Asian perspectives: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
-
Park SB, Kim KO, Lee HS, Choi CH, Wei SC, Chen MH, Matsuoka K
- KMID: 2544759
- Intest Res.
- 2023 Jul;21(3):363-374.
- doi: 10.5217/ir.2023.00015
Background/Aims: Long-term immunosuppressive therapies used to treat inflammatory bowel disease (IBD) are associated with an increased risk of infections, many of which can be prevented by vaccination. We assessed physicians’... -
- CITED
-
- Close
- SHARE
-
- Close
- Pathophysiology of Overactive Bladder and Pharmacologic Treatments Including β3-Adrenoceptor Agonists -Basic Research Perspectives-
-
Kwon J, Kim DY, Cho KJ, Hashimoto M, Matsuoka K, Kamijo T, Wang Z, Karnup S, Robertson AM, Tyagi P, Yoshimura N
- KMID: 2553091
- Int Neurourol J.
- 2024 Feb;28(Suppl 1):12-33.
- doi: 10.5213/inj.2448002.001
Overactive bladder (OAB) is a symptom-based syndrome defined by urinary urgency, frequency, and nocturia with or without urge incontinence. The causative pathology is diverse; including bladder outlet obstruction (BOO), bladder... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies
-
Kobayashi T, Matsuoka K, Watanabe M, Hisamatsu T, Hirai F, Milata J, Li X, Morris N, Arora V, Ishizuka T, Matsuo K, Satoi Y, Milch C, Hibi T
- KMID: 2554661
- Intest Res.
- 2024 Apr;22(2):172-185.
- doi: 10.5217/ir.2023.00043
Background/Aims: Mirikizumab is a p19-directed anti-interleukin-23 antibody with potential efficacy against ulcerative colitis (UC). We evaluated the efficacy and safety of mirikizumab in a Japanese subpopulation with moderately to severely... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunological Abnormalities in the Pathogenesis of Inflammatory Bowel Disease
-
Hisamatsu , Mikami Y, Matsuoka K, Kanai T, Hibi T
- KMID: 2174247
- Intest Res.
- 2012 Oct;10(4):317-323.
- doi: 10.5217/ir.2012.10.4.317
Crohn's disease and ulcerative colitis represent two distinct forms of inflammatory bowel diseases (IBD). In this paper, we discuss how immunological mechanisms contribute to the pathogenesis of IBD. Intestinal homeostasis... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
-
Hibi T, Motoya S, Hisamatsu T, Hirai F, Watanabe K, Matsuoka K, Saruta M, Kobayashi T, Feagan BG, Tasset C, Besuyen R, Yun C, Crans G, Zhang J, Kondo A, Watanabe M
- KMID: 2539010
- Intest Res.
- 2023 Jan;21(1):110-125.
- doi: 10.5217/ir.2021.00143
Background/Aims: The safety and efficacy of filgotinib, a once-daily oral Janus kinase 1 preferential inhibitor, were evaluated in Japanese patients with ulcerative colitis (UC) in the phase 2b/3 SELECTION trial. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Single fecal microbiota transplantation failed to change intestinal microbiota and had limited effectiveness against ulcerative colitis in Japanese patients
-
Mizuno S, Nanki K, Matsuoka K, Saigusa K, Ono K, Arai M, Sugimoto S, Kiyohara H, Nakashima , Takeshita , Naganuma M, Suda W, Hattori M, Kanai T
- KMID: 2368487
- Intest Res.
- 2017 Jan;15(1):68-74.
- doi: 10.5217/ir.2017.15.1.68
BACKGROUND/AIMS: Recent developments in analytical techniques including next-generation sequencing have clarified the correlation between intestinal microbiota and inflammatory bowel disease. Fecal microbiota transplantation (FMT) for patients with ulcerative colitis (UC)... -
- CITED
-
- Close
- SHARE
-
- Close
- β-(1,3)-Glucan derived from Candida albicans induces inflammatory cytokines from macrophages and lamina propria mononuclear cells derived from patients with Crohn's disease
-
Mori K, Naganuma M, Mizuno S, Suzuki H, Kitazume M, Shimamura , Chiba S, Sugita A, Matsuoka K, Hisamatsu , Kanai T
- KMID: 2417650
- Intest Res.
- 2018 Jul;16(3):384-392.
- doi: 10.5217/ir.2018.16.3.384
BACKGROUND/AIMS: Recent research has highlighted the importance of interactions between commensal fungi and intestinal inflammation. However, there are few studies investigating whether commensal fungi contribute to inflammation in patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan
-
Komoto S, Motoya S, Nishiwaki , Matsui T, Kunisaki R, Matsuoka K, Yoshimura , Kagaya T, Naganuma M, Hida N, Watanabe M, Hibi T, Suzuki Y, Miura S, Hokari R, Japanese study group for pregnant women with IBD
- KMID: 2425286
- Intest Res.
- 2016 Apr;14(2):139-145.
- doi: 10.5217/ir.2016.14.2.139
BACKGROUND/AIMS: Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402643
- Intest Res.
- 2018 Jan;16(1):17-25.
- doi: 10.5217/ir.2018.16.1.17
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
- Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment
-
Park DI, Hisamatsu , Chen M, Ng SC, Ooi CJ, Wei SC, Banerjee R, Hilmi IN, Jeen YT, Han DS, Kim HJ, Ran Z, Wu K, Qian J, Hu PJ, Matsuoka K, Andoh A, Suzuki Y, Sugano K, Watanabe M, Hibi T, Puri AS, Yang SK
- KMID: 2402642
- Intest Res.
- 2018 Jan;16(1):4-16.
- doi: 10.5217/ir.2018.16.1.4
Because anti-tumor necrosis factor (anti-TNF) therapy has become increasingly popular in many Asian countries, the risk of developing active tuberculosis (TB) among anti-TNF users may raise serious health problems in... -
- CITED
-
- Close
- SHARE
-
- Close
